A. Pendse

SARS-CoV-2 accelerated clearance using a novel nitric oxide nasal spray (NONS) treatment: A randomized trial

R. Kodgule, M. Tandon, S. Winchester, 2022, The Lancet Regional Health - Southeast Asia.

Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial

C. Caracta, Saiprasad Patil, H. Barkate, 2020, International Journal of Infectious Diseases.

Efficacy and Safety of Remogliflozin Etabonate, a New Sodium Glucose Co-Transporter-2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-Blind, Active-Controlled Trial

R. Kodgule, M. Dharmalingam, R. Gaikwad, 2020, Drugs.

A Randomized, Double-blind, Active-controlled Study of Remogliflozin Etabonate 100 mg plus Teneligliptin 10 mg Twice-daily versus Teneligliptin 20 mg Oncedaily as add-on to Metformin Monotherapy in Indian Diabetic Patients

R. Kodgule, H. Barkate, Sumit, 2022, Journal of Diabetes and Treatment.

Evaluation of the Safety and Efficacy of Favipiravir in Adult Indian Patients with Mild-to-Moderate COVID-19 in a Real-World Setting

Saiprasad Patil, H. Barkate, N. Karnik, 2022, International Journal of General Medicine.

Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial

C. Caracta, Saiprasad Patil, H. Barkate, 2020, International Journal of Infectious Diseases.

Efficacy and safety of single-inhaler triple therapy of glycopyrronium, formoterol and fluticasone in patients with COPD: a double-blind, randomised controlled trial

S. Salvi, R. Kodgule, Saiprasad Patil, 2021, ERJ Open Research.

Comparative efficacy and safety of glycopyrronium/formoterol fixed-dose combination versus glycopyrronium monotherapy in patients with moderate-to–severe COPD

S. Salvi, R. Kodgule, Saiprasad Patil, 2022, Lung India : official organ of Indian Chest Society.